Charles River Laboratories International Earnings
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Wed, Nov 4, 2026
Fiscal period
Sep/2026
EPS estimate
$2.97
Charles River Laboratories International earnings summary
Charles River Laboratories International is scheduled to report Sep/2026 earnings on Nov 4, 2026, with analysts expecting EPS of $2.97. In its most recent report on Aug 5, 2026 (Q2 2026), CRL posted EPS of $-0.03. Revenue for the quarter was $1.00 billion.
Quarterly EPS is down 102.8% from the same quarter a year earlier. Across the last 16 reports, CRL shares moved an average of 5.6% (in either direction) in the first trading session after results, rising 11 times and falling 5 times.
Summary generated from market data by MetaCap's automated system. Methodology
CRL earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $-0.03 | — | +4.7% |
| May 7, 2026 | — | $-0.30 | — | -15.1% |
| Feb 18, 2026 | — | $-5.57 | — | +5.7% |
| Nov 5, 2025 | — | $1.10 | — | -0.1% |
| Aug 6, 2025 | — | $1.06 | — | +5.3% |
| May 7, 2025 | — | $0.50 | — | +1.6% |
| Feb 19, 2025 | — | $-4.17 | — | +1.4% |
| Nov 6, 2024 | — | $1.33 | — | -12.8% |
| Aug 7, 2024 | — | $1.74 | — | +0.4% |
| May 9, 2024 | — | $1.30 | — | -2.9% |
| Feb 14, 2024 | — | $3.63 | — | +1.1% |
| Nov 8, 2023 | — | $1.69 | — | +9.9% |
| Aug 9, 2023 | — | $1.89 | — | -7.3% |
| May 11, 2023 | — | $2.01 | — | +3.7% |
| Feb 22, 2023 | — | $3.66 | — | +5.5% |
| Nov 2, 2022 | — | $1.88 | — | +11.8% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.